Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec 15;13(1):1498-1509.
doi: 10.18632/aging.202195. Epub 2020 Dec 15.

Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis

Luo Wenjing  1 , Feng Yuanzheng  1 , Jun-Ying Li  1 , Liang V Tang  1 , Hu Yu  1
Affiliations
Meta-Analysis

Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis

Luo Wenjing et al. Aging (Albany NY). .

Abstract

Background: The rapidly evolving coronavirus disease 2019 (COVID-19) has resulted in more than 24 million infections and 821 thousand deaths. However, a vaccine or specific drug is absent up to this date and more attention has been focused on the use of convalescent plasma (CP). Several articles have described the CP treatment for patients with SARS-CoV-2 infection. But a comprehensive systematic review with meta-analysis about the safety and efficacy of CP transfusion in SARS-CoV-2-infected patients has not been published. We conducted this study for a better understanding of the therapeutic significance of CP for patients with COVID-19.

Results: A fixed-effect model (I2=0.0%) was used on the 9 articles for quantitative analysis showing that the mortality of patients with COVID-19 treated with or without CP was statistically significant (RR=0.57 [0.44-0.74]). Subgroup analysis showed that the severely ill patients benefited more from CP than the critically ill patients. Our study concluded that clinical improvement in severe COVID-19 cases were obvious. Adverse events were few and the effect of convalescent plasma on reducing viral load was apparent.

Conclusions: Convalescent plasma therapy appears safe for COVID-19, and plasma treated patients have marked reductions in their serum viral loads and most are virus negative after transfusion. Patients with severe COVID-19 benefit more from the convalescent plasma transfusion than critical patients, and patients treated in early stage are more likely to survive.

Methods: We reviewed the scientific literature from four databases published from December 8, 2019 to August 20, 2020. Statistical analyses were performed with STATA (version 15.1; Stata Corporation, College Station, TX, USA). The frequency with 95% confidence intervals (CI) was assessed using fixed effect model in analyzing the overall mortality and p <0.05 was considered statistically significant.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma therapy; meta-analysis; systematic review.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors do not have any conflicts of interest to declare.

Figures

Figure 1
Figure 1
Forest plot of RR for mortality in patients with COVID-19.
Figure 2
Figure 2
Egger’s test for the publication bias.
Figure 3
Figure 3
Trim and fill method with fixed-effects model to further examine the publication bias.
Figure 4
Figure 4
Forest plot of RR for mortality in severe patients with COVID-19.
Figure 5
Figure 5
Forest plot of RR for mortality in critical patients with COVID-19.
See this image and copyright information in PMC

References

    1. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, Dean N, Longini I, Halloran ME, Xu B, Zhang X, Wang L, Liu W, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020. 10.1101/2020.02.10.20021675 - DOI
    1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323:1239–1242. 10.1001/jama.2020.2648 - DOI - PubMed
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–13. 10.1016/S0140-6736(20)30211-7 - DOI - PMC - PubMed
    1. “WHO”. from http://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020; 49:717–26. 10.1093/ije/dyaa033 - DOI - PMC - PubMed

Publication types